Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug

British Journal of Haematology

Volumn 108, Issue 2, 2000, Pages 391-393

  Kneller, A ^a   Raanani, P ^a   Hardan, I ^a   Avigdor, A ^a   Levi, I ^a   Berkowicz, M ^a   Ben Bassat, I ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Multiple myeloma; Thalidomide

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; LOMUSTINE; MELPHALAN; PREDNISONE; THALIDOMID GRUNENTHAL 100; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DRUG RESISTANCE; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECURRENT CANCER; SOMNOLENCE; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0034014693     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.01835.x     Document Type: Article

References (7)

1. Anderson, K.C., Hamblin, T.J. & Taylor, A. (1999) Management of multiple myeloma today. Seminars in Hematology, 36, 3-8.
2. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences USA, 91, 4082-4085.
3. Folkman, J. (1995) Clinical applications of research on angiogenesis. New England Journal of Medicine, 333, 1757-1763.
4. Munshi, N., Wilson, C.S., Penn, J., Epstein, J., Singhal, S., Hough, A., Sanderson, R., Desikan, R., Siegel, D., Mehta, J. & Barlogie, B. (1998) Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood, 92, 98a.
5. Singhal, S., Mehta, J., Eddlemon, P., Gray, P., Cromer, J., Desikan, R., Ayers, D., Siegel, D., Munshi, N., Anaisse, E., Kantarjian, H., Zeldis, J. & Barlogie, B. (1998) Marked anti-tumor effect from anti-angiogenesis therapy with thalidomide in high risk refractory multiple myeloma. Blood, 92, 318a.
6. Vacca, A., Ribatti, D., Roncalli, A., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
7. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. & Dammacco, F. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073.